

Highly profitable, high-growth telemedicine platform serving the German medical cannabis market





Highly profitable, high-growth telemedicine platform serving the German medical cannabis market

Unique opportunity to acquire a rapidly scaling, fully remote telemedicine and digital prescription, GDPR-compliant platform operating under the EU cross-border framework. The business connects over 20,000 patients with licensed doctors and pharmacies in Germany

Licence(s) Held

Operates under EU cross-border telemedicine framework (Physicians licensed in Germany & Poland). GDPR-compliant platform. No direct cannabis handling license required.

Listing Details

- Cyprus-based company operates a fully digital telemedicine platform, enabling remote consultations and digital prescriptions
- Launched in 2024, the platform has served approximately 20,000 patients and processed over 6,500 prescriptions per month
- Focused on deep process optimization to ensure scalability before launching targeted marketing campaigns, including Facebook advertising and affiliate marketing, and continues to implement new features to enhance user experience
- Profitable business with margins exceeding 60%, a current revenue run rate of ~€140,000 per month, and a forecasted €1.5M by year-end, reflecting ~20% annual growth
- Income is generated through patient appointment bookings, marketing services for pharmacies, partnerships with leading producers, and white-label product offerings.
- Operates efficiently with ~12 staff/freelancers, leveraging front-end and back-end freelance specialists
- Automated workflows reduce doctor consultation time by 90%, and the platform supports white-label functionality for rapid B2B expansion
- Projected annual growth of 15–20% is driven by rising patient demand and recent liberalization of the German cannabis market

GROSS REVENUE

\$1,680,000

EBITDA

\$1,008,000

BUSINESS TYPE

Health Care Businesses

COUNTRY

Cyprus

BUSINESS ID

L#20261003

- Seeking full sale and includes the going concern business, intellectual property, brand, patient database, and software codebase

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction.

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



WWW.MERGERSCORP.COM